Jan-Stephan F Sanders1, Anoek A E de Joode1, Ruud G DeSevaux2, Jan Broekroelofs3, Alexandre E Voskuyl4, Pieter van Paassen5, Cees G M Kallenberg6, Jan Willem Cohen Tervaert5, Coen A Stegeman1. 1. Division of Nephrology, Department of Internal Medicine, University Medical Center Groningen, Groningen, The Netherlands. 2. Radboud University Medical Center, Nijmegen, The Netherlands. 3. Medical Center Leeuwarden, Leeuwarden, The Netherlands. 4. VU University Medical Center, Amsterdam, The Netherlands. 5. Maastricht University, Maastricht, The Netherlands. 6. Department of Rheumatology and Clinical Immunology, University Medical Center Groningen, Groningen, The Netherlands.
Abstract
BACKGROUND: Cytoplasmic anti-neutrophil cytoplasmic antibody (C-ANCA) positivity at remission has been associated with an increased relapse rate in patients with proteinase 3 anti-neutrophil cytoplasmic antibody-associated vasculitis (PR3-AAV) after a switch toazathioprine maintenance therapy. We therefore hypothesized that extended azathioprine maintenance therapy could reduce the incidence of relapse in this setting. METHODS:Patients newly diagnosed with PR3-AAV at 12 centres in The Netherlands during 2003-11 who received a standardized induction regimen consisting oforal cyclophosphamide and corticosteroids were enrolled (n = 131). Patients were randomized to standard or extended azathioprine maintenance therapy when C-ANCA was positive at the time of stable remission. Standard maintenance treatment consisted of azathioprine (1.5-2.0 mg/kg) until 1 year after diagnosis and subsequent tapering to 25 mg every 3 months. Extended azathioprine maintenance therapy (1.5-2.0 mg/kg) was continued until 4 years after diagnosis and tapered thereafter. The primary endpoint was relapse-free survival at 4 years after diagnosis. RESULTS: In patients with PR3-AAV who were C-ANCA positive at the time of stable remission, relapse-free survival at 4 years after diagnosis did not differ significantly between standard azathioprine (n = 24) and extended azathioprine (n = 21) maintenance therapy (P = 0.40). There was also no significant difference in relapse-free survival between patients receiving standard azathioprine (n = 106) versus extended azathioprine maintenance therapy (n = 21; P = 0.94). In addition, there was no difference in the relapse rate between patients with PR3-AAV who were C-ANCA positive (n = 45) at the time of remission versus patients who became C-ANCA negative at the time of remission (n = 82; P = 0.62). CONCLUSIONS: This randomized trial suggests that extended azathioprine maintenance therapy has only a limited effect on the prevention of relapse in patients with PR3-AAV at 4 years after diagnosis. Moreover, positive C-ANCA status at stable remission was not associated with an increased rate of relapse. TRIAL REGISTRATION: ClinicalTrials.gov NCT 00128895.
RCT Entities:
BACKGROUND: Cytoplasmic anti-neutrophil cytoplasmic antibody (C-ANCA) positivity at remission has been associated with an increased relapse rate in patients with proteinase 3 anti-neutrophil cytoplasmic antibody-associated vasculitis (PR3-AAV) after a switch to azathioprine maintenance therapy. We therefore hypothesized that extended azathioprine maintenance therapy could reduce the incidence of relapse in this setting. METHODS:Patients newly diagnosed with PR3-AAV at 12 centres in The Netherlands during 2003-11 who received a standardized induction regimen consisting of oral cyclophosphamide and corticosteroids were enrolled (n = 131). Patients were randomized to standard or extended azathioprine maintenance therapy when C-ANCA was positive at the time of stable remission. Standard maintenance treatment consisted of azathioprine (1.5-2.0 mg/kg) until 1 year after diagnosis and subsequent tapering to 25 mg every 3 months. Extended azathioprine maintenance therapy (1.5-2.0 mg/kg) was continued until 4 years after diagnosis and tapered thereafter. The primary endpoint was relapse-free survival at 4 years after diagnosis. RESULTS: In patients with PR3-AAV who were C-ANCA positive at the time of stable remission, relapse-free survival at 4 years after diagnosis did not differ significantly between standard azathioprine (n = 24) and extended azathioprine (n = 21) maintenance therapy (P = 0.40). There was also no significant difference in relapse-free survival between patients receiving standard azathioprine (n = 106) versus extended azathioprine maintenance therapy (n = 21; P = 0.94). In addition, there was no difference in the relapse rate between patients with PR3-AAV who were C-ANCA positive (n = 45) at the time of remission versus patients who became C-ANCA negative at the time of remission (n = 82; P = 0.62). CONCLUSIONS: This randomized trial suggests that extended azathioprine maintenance therapy has only a limited effect on the prevention of relapse in patients with PR3-AAV at 4 years after diagnosis. Moreover, positive C-ANCA status at stable remission was not associated with an increased rate of relapse. TRIAL REGISTRATION: ClinicalTrials.gov NCT 00128895.
Authors: Matthew David Morgan; Matthew Szeto; Michael Walsh; David Jayne; Kerstin Westman; Niels Rasmussen; Thomas F Hiemstra; Oliver Flossmann; Annelies Berden; Peter Höglund; Lorraine Harper Journal: Arthritis Res Ther Date: 2017-06-07 Impact factor: 5.156
Authors: Susan L Hogan; Patrick H Nachman; Caroline J Poulton; Yichun Hu; Lauren N Blazek; Meghan E Free; J Charles Jennette; Ronald J Falk Journal: Kidney Int Rep Date: 2019-01-28